Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States-Reference-Cited by-同舟云学术

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States

Published:2024-05-10 Issue:2 Volume:11 Page:209-219
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Harding Lisa,Joshi Kruti,Zhdanava Maryia^ORCID,Shah Aditi,Voegel Arthur,Chen Cindy,Pilon Dominic

Funder

Janssen Scientific Affairs, LLC

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40801-024-00425-2.pdf

Reference24 articles.

1. Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2).

2. Li G, Zhang L, DiBernardo A, et al. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients. PLoS ONE. 2020;15(9): e0238843.

3. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–34.

4. Wang SM, Kim NY, Na HR, et al. Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis. Clin Psychopharmacol Neurosci. 2021;19(2):341–54.

5. Cheng Q, Huang J, Xu L, et al. Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression. Int J Neuropsychopharmacol. 2020;23(2):76–87.